Coloplast A/S (OTCMKTS:CLPBY) Raised to Moderate Buy at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Coloplast A/S (OTCMKTS:CLPBY) from a hold rating to a moderate buy rating in a report published on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th. Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th.

Coloplast A/S Stock Up 1.1 %

Shares of OTCMKTS:CLPBY opened at $11.10 on Monday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.66 and a current ratio of 1.02. Coloplast A/S has a 1-year low of $10.54 and a 1-year high of $14.34. The company has a 50 day moving average price of $11.11 and a 200 day moving average price of $12.26.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. As a group, equities analysts forecast that Coloplast A/S will post 0.31 earnings per share for the current fiscal year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.